In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.
about
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateMetformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent mannersPhase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Targeting MYC Dependence by Metabolic Inhibitors in CancerImpact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice.A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expressionTargeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.Exploiting novel molecular targets in gastrointestinal cancers.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responsesPhase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinActivity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.Human cancer growth and therapy in immunodeficient mouse models.Defining the role of TORC1/2 in multiple myeloma.Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgraftsPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus).Modeling resistance to pathway-targeted therapy in ovarian cancerNovel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Investigational treatments for multiple myeloma.Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.Preclinical studies of novel targeted therapies.Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.From the bench to the bedside: emerging new treatments in multiple myeloma.Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cellsFDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesTORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Novel therapeutic targets for multiple myeloma.Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.Mammalian target of rapamycin as a target in hematological malignancies.The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
P2860
Q28067598-42232685-F397-46D9-979E-C6006A586B26Q28486318-B725CE5D-42C5-4354-A96E-A621C2C020B7Q33383550-4E21EB66-910F-4F59-9DA0-35DB0B97ECFEQ33414529-47A1272E-FAE9-48A7-9A64-2BB446DD0DDEQ33414827-6D5DB6FE-6506-4288-9990-016B9CE2EFDDQ33608493-2B22D461-AD42-4915-AC34-432DB4867248Q33707315-44C8D4E7-106A-4BF4-9EB8-6DD62CCCB3D0Q33769618-AC499862-B851-48E4-8073-D72A6216CEBBQ33829094-79F7630B-D0F7-4074-B341-B0B5DF308EFDQ34083360-B18FB1BC-FB2A-4B25-8CE6-12CB99A91A47Q34374071-949B1FAA-37A8-402C-939E-3AE1540B0B5DQ34382777-EE61B346-CD61-4191-AA93-C2B32302D4C1Q34773850-C2566263-7FD0-4450-A8CD-9C11EC2A9435Q35142765-4E50C96B-BEC3-449D-BC61-AB210B88917AQ35187824-B342FBA1-D950-45AD-AFF6-8AFF926100FFQ35236076-AAEC8327-CB91-4983-9223-9295070FAD41Q35545282-EC996E0E-9FF2-4331-89E3-47E18FD74DB8Q35631315-5EB31874-A5E0-4D35-AB2A-085F08932C8CQ35798540-58878FAF-D4BB-4529-938D-45B600541A5CQ35913613-C43AB706-1D2B-495E-98DA-485F56639ADCQ35932363-628C7B0D-F07E-4442-800D-9132679F40DEQ36045128-03D3D9D0-58E8-4C69-B813-B2BB087923A7Q36170527-63637C44-EB0F-4194-B7AA-19CA3C2A308CQ36367811-87761D4C-76DE-4268-A3E3-521BA0EA337FQ36600294-5A9A763C-3767-4675-9EBD-157A41549370Q36654336-B694439E-5A01-41D9-A123-55D00CE22B10Q36844334-031A65CF-6198-4B31-9558-8FF9DC10C0A5Q36998210-6DE8B625-2D6E-4E82-8AF4-93945343DB03Q37028215-9269E65B-F70C-4993-B5A2-B33ECAC2F383Q37028598-1FF59AF7-8F10-4FC0-A438-3424934CF026Q37074284-07E17734-2597-41E5-97BC-B0B751DA1ED9Q37132224-71817FB4-54DC-4813-8A9A-F12485CB28C1Q37225698-E1C2CABF-F783-44EB-8600-812174815653Q37432231-C0008D34-9350-44B9-84E0-8319EA6CA0D5Q37672563-C6CBC85B-5C19-4ED3-B7CA-875C679785C7Q37697253-7D0185C1-C2E3-4F19-80E0-16A2995CA458Q37707383-A7B2C358-BAA0-4B02-BBF1-CEC6B65E9495Q37779489-6563DCB0-6B59-4A7B-AD04-01A3456F0FB2Q37866136-50B63F38-2E57-42A4-979B-24086DBDD217Q37877729-F49AD359-A1C3-478B-A212-A79AD9CD5EBA
P2860
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@ast
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@en
type
label
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@ast
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@en
prefLabel
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@ast
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@en
P2093
P1433
P1476
In vivo antitumor effects of t ...... ma cells in a xenograft model.
@en
P2093
Alan Lichtenstein
Farhad Moatamed
Huajun Yan
Jay Gibbons
Joseph Gera
Philip Frost
Yijiang Shi
P304
P356
10.1182/BLOOD-2004-03-1153
P407
P577
2004-08-10T00:00:00Z